Why the study?
Does BN 52021 reduce 28-day all-cause mortality in patients with sepsis syndrome?
Population
262 patients with sepsis syndrome
Comparison
BN 52021 120 mg intravenously every 12 hrs over… vs Placebo added to standard supportive care and…
Design
RCT, randomized, double-blind
Follow-up
28 days
Authors
Loading...
BN 52021 does not reduce 28-day mortality in sepsis syndrome; leaves open possible benefit in Gram-negative sepsis.
Does BN 52021 reduce 28-day all-cause mortality in patients with sepsis syndrome?
BN 52021 did not significantly reduce 28-day mortality in the overall sepsis syndrome population, but showed potential benefit in the subgroup with Gram-negative sepsis.
Dhainaut et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: